At the 10-unit starting dose, 2,667 mcg of total blend works out to roughly 1,667 mcg GHK-Cu plus ~333 mcg each of BPC-157, KPV and TB-500

Common side effects (usually mild) Injection-related: Injection site redness or irritation Mild pain at injection site Temporary skin induration GH-related: Water retention (usually temporary) Mild headaches (especially initially) Increased hunger (less than GHRP-6) Tingling or numbness (rare, usually at high doses) Sleep-related: Vivid dreams (often reported, not necessarily unpleasant) Temporary sleep disturbance during adjustment Less common side effects At higher doses or prolonged use: Joint stiffness or mild carpal tunnel symptoms Flushing Dizziness Fatigue (paradoxically, sometimes) What Ipamorelin typically doesn't cause Unlike other GHRPs: No significant cortisol elevation No significant prolactin increase No intense hunger spikes No blood sugar disruption Managing side effects For water retention: Usually resolves within 2-4 weeks Reduce sodium intake Stay well-hydrated Consider reducing dose temporarily For headaches: Often occur during first week Ensure proper hydration Start with lower dose and titrate up Usually resolve with continued use For injection site reactions: Rotate injection sites Ensure proper injection technique Allow alcohol to dry before injecting Use fresh needles Contraindications Do not use Ipamorelin if you have: Active cancer or history of cancer Uncontrolled diabetes Severe cardiovascular disease Pregnancy or breastfeeding Known allergy to peptide components Use with caution if you have: Diabetes (monitor blood sugar closely) History of carpal tunnel syndrome Pituitary disorders Any condition affected by growth hormone For comprehensive safety information, see our peptide safety guide

PEX-168 is a new agent of long-acting GLP-1R agonist, which is molecularly modified from EX via amino acid modification and PEGylation (119), the first GLP-1R agonist modified by PEG to achieve long-term pharmacological action (120, 121)
Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure
2.3 Patients with Type 1 Diabetes Reduce mealtime insulin doses by 50%, then initiate SYMLIN at 15 mcg subcutaneously, injecting immediately prior to each major meal